Sugi Predict

Sugi Predict / Compounds / SCHEMBL2278303

SCHEMBL2278303

SCHEMBL2278303

COC(=O)C1(C)CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ EPHX2 P34913 1/20 0.40
▸ NR1H2 P55055 3/20 0.40
▸ EPHX1 P07099 1/20 0.39
▸ HPGD P15428 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ RECQL P46063 1/20 0.36
▸ LMNA P02545 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ PTPN2 P17706 1/20 0.35
▸ PTPN1 P18031 1/20 0.35
▸ PTPN6 P29350 1/20 0.35
▸ RORC P51449 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2673515 0.87 USP2 (0.42) USP2SMN1; SMN2EPHX2NR1H2EPHX1
SCHEMBL25209207 0.87 USP2 (0.42) USP2SMN1; SMN2EPHX2NR1H2EPHX1
SCHEMBL25263085 0.86 EPHX2 (0.37) USP2SMN1; SMN2EPHX2NR1H2EPHX1
SCHEMBL3157569 0.84 HPGD (0.41) USP2SMN1; SMN2EPHX2NR1H2EPHX1
SCHEMBL19080547 0.83 USP2 (0.39) USP2SMN1; SMN2EPHX2NR1H2EPHX1
SCHEMBL2420832 0.83 USP2 (0.49) USP2SMN1; SMN2EPHX2EPHX1HPGD
SCHEMBL28974224 0.82 USP2 (0.38) USP2SMN1; SMN2EPHX2NR1H2EPHX1
SCHEMBL22118612 0.82 USP2 (0.43) USP2SMN1; SMN2EPHX2NR1H2EPHX1
SCHEMBL19091341 0.82 USP2 (0.43) USP2SMN1; SMN2EPHX2NR1H2EPHX1
SCHEMBL15116747 0.81 USP2 (0.46) USP2SMN1; SMN2EPHX2NR1H2EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240408064-A1 RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF GENETOLEAD INC. (CA) 2024-12-12 — — US disclosed
WO-2023060362-A1 RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF GENETOLEAD INC. (CA) 2023-04-20 — — WO disclosed
US-20230036854-A1 HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS THE UNIVERSITY OF SHEFFIELD (GB) 2023-02-02 — — US disclosed
US-20230026696-A1 TRPV4 RECEPTOR LIGANDS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-01-26 — — US disclosed
US-20230026696-A1 TRPV4 RECEPTOR LIGANDS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-01-26 — — US disclosed
EP-4061124-A1 TRPV4 RECEPTOR LIGANDS University of Utah Research Foundation (US) 2022-09-28 — — EP disclosed
CN-115052478-A TRPV4 receptor ligands 犹他大学研究基金会 2022-09-13 — — CN disclosed
CN-113474337-A 7- ((3, 5-dimethoxyphenyl) amino) quinoxaline derivatives as FGFR inhibitors for the treatment of cancer 奥瑞生物药品公司 2021-10-01 — — CN disclosed
WO-2021102314-A1 TRPV4 RECEPTOR LIGANDS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2021-05-27 — — WO disclosed
CN-112300159-A Dual ATM and DNA-PK inhibitors for use in antitumor therapy 艾科思莱德制药公司 2021-02-02 — — CN disclosed
WO-2011095452-A1 ARYL BENZYLAMINE COMPOUNDS NOVARTIS AG (CH) 2011-08-11 — — WO disclosed
US-20110190258-A1 ARYL BENZYLAMINE COMPOUNDS NOVARTIS AG (CH) 2011-08-04 — — US disclosed
US-20110190258-A1 ARYL BENZYLAMINE COMPOUNDS NOVARTIS AG (CH) 2011-08-04 — — US disclosed
US-20110190258-A1 ARYL BENZYLAMINE COMPOUNDS NOVARTIS AG (CH) 2011-08-04 — — US disclosed
US-20090227555-A2 Novel Pyridine Compounds ASTRAZENECA AB (SE) 2009-09-10 — — US disclosed
US-20090042852-A1 Novel Pyridine Compounds ASTRAZENECA AB (SE) 2009-02-12 — — US disclosed
CN-101137643-A Novel pyridine compounds ASTRAZENECA AB (SE) 2008-03-05 — — CN disclosed
EP-1836189-A1 NOVEL PYRIDINE COMPOUNDS AstraZeneca AB (SE) 2007-09-26 — — EP disclosed
WO-2006073361-A9 NOVEL PYRIDINE COMPOUNDS ASTRAZENECA AB (SE) 2007-08-02 — — WO disclosed
WO-2006073361-A1 NOVEL PYRIDINE COMPOUNDS ASTRAZENECA AB (SE) 2006-07-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042852-A1 Novel Pyridine Compounds P2RY12, P2RY11, P2RY1 USP2 4256/4885SMN1; SMN2 3557/4885EPHX2 1891/4885
US-20090227555-A2 Novel Pyridine Compounds P2RY12, P2RY1, P2RY11 USP2 4208/4885SMN1; SMN2 4121/4885EPHX2 1151/4885
US-20240408064-A1 RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF KRAS, NRAS, HRAS USP2 1168/4885SMN1; SMN2 3808/4885EPHX2 956/4885
US-20230026696-A1 TRPV4 RECEPTOR LIGANDS TRPV4, TRPV2, TRPV3 USP2 4576/4885SMN1; SMN2 4557/4885EPHX2 3104/4885
US-20230036854-A1 HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS MC2R, AGTR2, NR3C2 USP2 4419/4885SMN1; SMN2 1891/4885EPHX2 400/4885
US-20110190258-A1 ARYL BENZYLAMINE COMPOUNDS UGT2B7, NAT1, CYP2B6 USP2 3022/4885SMN1; SMN2 1805/4885EPHX2 2012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.